Mestag Therapeutics

Mestag Therapeutics discovers, develops and delivers impactful precision medicines into disease-driving fibroblast subpopulations.

Mestag was founded in 2020 to develop new medicines for people affected by inflammatory disease and cancer.

The company develops impactful therapies for patients by targeting activated fibroblast populations and determining their role in influencing the immune system in disease. Mestag’s founding investigators comprise leading experts in inflammatory disease, cancer, computational biology and fibroblast biology united in a common vision of the role of fibroblasts in disease: Professor Michael Brenner (Brigham and Women’s Hospital & Harvard Medical School), Professor Chris Buckley (Oxford Kennedy Institute, University of Oxford), Professor David Tuveson (Cold Spring Harbor Laboratory and President of AACR), Professor Soumya Raychaudhuri (Harvard Medical School & Broad Institute) and Professor Mark Coles (Oxford Kennedy Institute, University of Oxford).

The Mestag team is progressing a pipeline of first in class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and immuno-oncology. Mestag is headquartered in Cambridge, UK. For more information, visit www.mestagtx.com